Cellular Adhesion Affecting Or Cell Adhesion Molecule (cam) Affecting Or Utilizing Patents (Class 514/19.1)
-
Patent number: 11733233Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.Type: GrantFiled: July 21, 2020Date of Patent: August 22, 2023Assignee: CELGENE CORPORATIONInventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
-
Patent number: 11021514Abstract: The present technology relates to compounds, kits, compositions, and methods useful for the treatment of numerous pathologies including dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, defective wound healing, and/or sensorineural hearing and vision loss.Type: GrantFiled: June 1, 2017Date of Patent: June 1, 2021Assignee: Athira Pharma, Inc.Inventors: Leen H. Kawas, Jasbir Singh, Lansing Joseph Stewart, William R. Baker
-
Patent number: 10830762Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.Type: GrantFiled: December 27, 2016Date of Patent: November 10, 2020Assignee: CELGENE CORPORATIONInventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
-
Patent number: 10646541Abstract: Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.Type: GrantFiled: March 26, 2015Date of Patent: May 12, 2020Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventor: Randolph S. Watnick
-
Patent number: 10428329Abstract: Novel processes and compositions are described which use viral capsid proteins resistant to hydrolases to prepare virus-like particles to enclose and subsequently isolate and purify target cargo molecules of interest including nucleic acids such as siRNAs and shRNAs, miRNAs, messenger RNAs, small peptides and bioactive molecules.Type: GrantFiled: October 17, 2017Date of Patent: October 1, 2019Assignee: APSE, INC.Inventors: Juan Pedro Humberto Arhancet, Juan P. Arhancet, Kimberly Delaney, Kathleen B. Hall, Neena Summers, Edward Oates
-
Patent number: 10106580Abstract: Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment.Type: GrantFiled: October 27, 2015Date of Patent: October 23, 2018Assignee: Brown UniversityInventor: Jason K. Sello
-
Patent number: 9878013Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13R?2 protein.Type: GrantFiled: February 17, 2016Date of Patent: January 30, 2018Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Mazess Herpai
-
Patent number: 9846153Abstract: A device for determining the presence of an analyte in a sample uses a substrate shaped to define a plurality of lateral-flow channels and a detection region. Each lateral-flow channel is associated with a load spot. The substrate includes, for each of the lateral-flow channels, a fluid conducting medium, and, for the detection region, a fluid retaining medium. A first load spot receives a sample from the subject. Each of the other load spots uses a dried mixture of silk fibroin with a reagent. The detection region includes a detection reagent including a first immunoreactant. A second load spot includes a secondary detection immunoreactant. A third load spot includes a color reagent. The device implements an ELISA reaction when activated by sequentially placed aliquots of an aqueous solution.Type: GrantFiled: May 15, 2017Date of Patent: December 19, 2017Inventor: Olivia A. Hallisey
-
Patent number: 9708384Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.Type: GrantFiled: September 24, 2012Date of Patent: July 18, 2017Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
-
Patent number: 9505787Abstract: The present invention provides improved processes for the preparation of Bortezomib, tert -butyl[1-({(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate of formula (IV) and N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl} phenylalanine of formula (V). Compound (IV) is prepared by coupling (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethyl-hexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butan-1-amine of formula (II) or its salt with N-(tert-butoxycarbonyl)-L -phenylalanine of formula (III) in a first solvent in the presence of a first coupling agent and a first base, wherein the coupling process does not comprise solvent exchange. Compound (V) is prepared by deprotecting compound (IV) using an alcoholic solution of an inorganic acid.Type: GrantFiled: September 11, 2013Date of Patent: November 29, 2016Assignee: Cipla LimitedInventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Srinivas Laxminarayan Pathi, Ravikumar Puppala
-
Patent number: 9470689Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.Type: GrantFiled: December 31, 2013Date of Patent: October 18, 2016Assignee: The Regents of the University of CaliforniaInventor: Robert E. Reiter
-
Patent number: 9428550Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.Type: GrantFiled: January 16, 2013Date of Patent: August 30, 2016Assignee: Governing Council of the University of TorontoInventor: Paulo Koeberle
-
Publication number: 20150140005Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Inventors: Keith R. Walley, John H. Boyd, James A. Russell
-
Publication number: 20150051152Abstract: The invention relates to a cyclic peptide increasing the fusiogenic capacity of the oocyte arising from the disintegrin loop of fertilin beta, to a pharmaceutical composition comprising said cyclic peptide and to the use thereof, particularly in order to supplement culture media used to carry out in vitro fertilization.Type: ApplicationFiled: October 28, 2014Publication date: February 19, 2015Inventors: Morgane BOMSEL, Jean-Philippe WOLF
-
Patent number: 8940700Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.Type: GrantFiled: August 18, 2010Date of Patent: January 27, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: John M. Hallenbeck, Hideaki Wakita
-
Publication number: 20150004205Abstract: The invention generally relates to surfaces having a protein-resistant hydrogel layer and methods for preparing a protein-resistant hydrogel layer on a surface. The protein-resistant hydrogel layer is formed by a protein-crosslinked water soluble polymer that is contacted with a surface to form a thin protein-resistant hydrogel layer on the surface.Type: ApplicationFiled: June 18, 2014Publication date: January 1, 2015Inventors: Donald Elbert, Megan Kaneda, Evan Scott, Brad Wacker
-
Publication number: 20140377320Abstract: A treated surface of a device (10) for implantation or for application as a wound dressing, comprises an array of plasma-activated hydrophilic cell-adhesive areas (18) having the ability to reduce fibrous reaction, is in the form of an array of islets of activation. Each islet of activation (18) has a length which is less than 6 ?m, a width which is less than 2 ?m and the distance between islets is preferably from 4 ?m to 6 ?m. The islets of activation (18) are surrounded by non-activated, non-adhesive, hydrophobic areas.Type: ApplicationFiled: December 21, 2012Publication date: December 25, 2014Inventors: Giorgio Pietramaggiori, Hicham Majd
-
Publication number: 20140342990Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: ApplicationFiled: July 29, 2014Publication date: November 20, 2014Inventor: Ming Zhang
-
Patent number: 8889628Abstract: Recombinant proteins comprised of multiple selectin binding domains derived from the glycopeptide PSGL-1, in a novel tandem configuration, are disclosed, including their fusions with immunoglobulins and/or other polypeptides. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.Type: GrantFiled: November 28, 2012Date of Patent: November 18, 2014Inventor: Gray D Shaw
-
Patent number: 8883738Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.Type: GrantFiled: December 13, 2012Date of Patent: November 11, 2014Assignee: Karisruher Insitut für TechnologieInventors: Alexandra Matzke, Helmut Ponta, Véronique Orian-Rousseau, Martina Tremmel
-
Patent number: 8877712Abstract: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells, whereby survival or differentiation of chondrocytes at the site is enhanced, thereby ultimately enhancing bone density or formation. Methods and compositions for stimulating hair regrowth are also provided.Type: GrantFiled: April 6, 2007Date of Patent: November 4, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: George P Yang, Jonathan A. Mathy, Thomas Quertermous
-
Patent number: 8871718Abstract: Transglutaminase inhibitors and methods of use thereof are provided.Type: GrantFiled: December 4, 2012Date of Patent: October 28, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chaitan Khosla, Richard Edward Watts, Matthew John Siegel, Kihang Choi
-
Patent number: 8840874Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.Type: GrantFiled: November 24, 2010Date of Patent: September 23, 2014Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Ayelet David, Gonen Ashkensy, Yosi Shamay
-
Publication number: 20140271469Abstract: Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin ?v?6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in ?v?6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin ?v?6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.Type: ApplicationFiled: May 21, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Richard H. Kimura, Sanjiv S. Gambhir, Benjamin J. Hackel, Robert Teed, Bin Shen, Frederick T Chin, Zhen Cheng
-
Publication number: 20140255421Abstract: The invention relates generally to methods and compositions for treating sinusitis, asthma, or polyps. The invention also relates to methods and compositions for treating nasal polyps.Type: ApplicationFiled: February 12, 2014Publication date: September 11, 2014Applicant: Massachusetts Eye and Ear InfirmaryInventors: Konstantina M. Stankovic, Ralph Metson
-
Patent number: 8828417Abstract: For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration.Type: GrantFiled: July 8, 2008Date of Patent: September 9, 2014Assignee: Corlife OHGInventors: Andres Hilfiker, Denise Hilfiker-Kleiner, Artur Lichtenberg
-
Patent number: 8815805Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: November 7, 2012Date of Patent: August 26, 2014Assignee: California Northstate College of Pharmacy, LLCInventor: Xiaodong Feng
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8791073Abstract: Peptide-modified polyurethanes comprising the reaction product of an isocyanate, a chain extender, and a peptide are provided. Also provided processes for making a peptide-modified polyurethane comprising: providing an isocyanate; providing a chain extender; providing a peptide; and allowing the isocyanate, chain extender, and peptide to react thereby forming the peptide-modified polyurethane, as well as methods for treating a subject comprising: providing a peptide-modified polyurethane that comprises the reaction product of an isocyanate, a chain extender, and a peptide; and administering the peptide-modified polyurethane to the subject.Type: GrantFiled: May 16, 2005Date of Patent: July 29, 2014Assignee: William Marsh Rice UniversityInventors: Jennifer L. West, Ho-Wook Jun, Lakeshia J. Taite
-
Patent number: 8785395Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: May 3, 2011Date of Patent: July 22, 2014Assignees: The Texas A & M University System, Temple Therapeutics, Inc.Inventors: Darwin J. Prockop, Joo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz
-
Patent number: 8765682Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.Type: GrantFiled: June 14, 2013Date of Patent: July 1, 2014Assignee: Postech Academy-Industry FoundationInventors: Hyung Joon Cha, Byeongseon Yang, Yoo Seong Choi, Hyungdon Yun
-
Patent number: 8685925Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.Type: GrantFiled: July 10, 2007Date of Patent: April 1, 2014Assignee: Nono Inc.Inventor: Michael Tymianski
-
Patent number: 8680057Abstract: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.Type: GrantFiled: May 14, 2012Date of Patent: March 25, 2014Assignee: Rhode Island HospitalInventor: Gregory D. Jay
-
Publication number: 20140080762Abstract: The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as ?4 integrin and CD44 expression.Type: ApplicationFiled: March 21, 2012Publication date: March 20, 2014Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Lori Anne Hazlehurst, William S. Dalton, Michael Emmons, Anthony W. Gebhard
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Patent number: 8637465Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.Type: GrantFiled: May 27, 2009Date of Patent: January 28, 2014Assignee: Kobenhavns UniversitetInventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
-
Patent number: 8614191Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (A?), a cause of dementia, and is thus useful in preventing or treating a neurological disease including Alzheimer's disease.Type: GrantFiled: February 2, 2012Date of Patent: December 24, 2013Assignee: Medipost Co., Ltd.Inventors: Yoon-Sun Yang, Won Il Oh, Jong Wook Chang, Ji Hyun Kim
-
Patent number: 8603986Abstract: Peptides comprising a cadherin cell adhesion recognition (CAR) sequence, and compositions comprising such peptides, are provided. Methods of using such peptides for modulating cadherin-mediated processes in a variety of therapeutic contexts are also provided. Methods are also provided for identifying compounds that are capable of modulating cadherin-mediated processes.Type: GrantFiled: April 28, 2006Date of Patent: December 10, 2013Assignee: McGill UniversityInventors: Orest W. Blaschuk, Emmanuelle Marie-Madeleine Devemy
-
Patent number: 8563514Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: GrantFiled: August 14, 2008Date of Patent: October 22, 2013Assignee: MetamorefixInventors: Mazal Dahan, Raphael Gorodetsky
-
Patent number: 8563515Abstract: The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.Type: GrantFiled: November 19, 2008Date of Patent: October 22, 2013Assignee: The Regents of the University of Colorado, a body corporateInventors: Margaret C. Neville, Neal Beeman, Robert S. Hodges
-
Publication number: 20130225495Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: ApplicationFiled: November 7, 2012Publication date: August 29, 2013Applicant: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACYInventor: CALIFORNIA NORTHSTATE COLLEGE OF PHAR
-
Patent number: 8470782Abstract: Transglutaminase inhibitors and methods of use thereof are provided.Type: GrantFiled: August 28, 2006Date of Patent: June 25, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chaitan Khosla, Richard Edward Watts, Matthew John Siegel, Daniel M. Pinkas, Kihang Choi, Keith M. Rich
-
Publication number: 20130129621Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.Type: ApplicationFiled: May 9, 2012Publication date: May 23, 2013Applicant: ALLEGRO PHARMACEUTICALS, INC.Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
-
Publication number: 20130084292Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.Type: ApplicationFiled: April 15, 2011Publication date: April 4, 2013Applicant: UNIVERSITE D'AUVERGNE CLERMONT IInventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
-
Publication number: 20130072435Abstract: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.Type: ApplicationFiled: May 14, 2012Publication date: March 21, 2013Applicant: Rhode Island HospitalInventor: Gregory D. Jay
-
Publication number: 20130045924Abstract: The present invention provides a use of soluble P-selectin in treating systemic hemorrhagic conditions, stabilizing blood pressure, and protecting hypoxic/ischemic tissues. Also provided is a use of anthrax lethal toxin in treating thrombotic conditions.Type: ApplicationFiled: December 29, 2006Publication date: February 21, 2013Inventors: Hsin-Hou Chang, Der-Shan Sun
-
Patent number: 8377887Abstract: The present invention provides a use of soluble P-selectin in treating systemic hemorrhagic conditions, stabilizing blood pressure, and protecting hypoxic/ischemic tissues. Also provided is a use of anthrax lethal toxin in treating thrombotic conditions.Type: GrantFiled: December 29, 2006Date of Patent: February 19, 2013Inventors: Hsin-Hou Chang, Der-Shan Sun
-
Patent number: 8357655Abstract: Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided.Type: GrantFiled: January 8, 2009Date of Patent: January 22, 2013Assignee: Tufts UniversityInventor: Ira M. Herman
-
Publication number: 20120328632Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: December 21, 2011Publication date: December 27, 2012Applicant: Genentech, Inc.Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Patent number: 8338365Abstract: This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of ?IIb?3, ?v?3, ?v?5, or ?5?1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.Type: GrantFiled: February 6, 2012Date of Patent: December 25, 2012Assignee: University of Southern CaliforniaInventors: Radu O. Minea, Francis S. Markland, Jr.